HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 3-week cycles.

AbstractBACKGROUND:
Imiquimod 5% cream is approved as a 16-week regimen for the treatment of actinic keratoses involving a 25-cm(2) area of skin.
OBJECTIVE:
We sought to evaluate imiquimod 2.5% and 3.75% creams for short-course treatment of the entire face and scalp.
METHODS:
In two identical studies, adults with 5 to 20 lesions were randomized to placebo, or imiquimod 2.5% or 3.75% cream (1:1:1). Up to two packets (250 mg each) were applied per dose once daily for two 3-week treatment cycles, with a 3-week, no-treatment interval. Efficacy was assessed at 8 weeks posttreatment.
RESULTS:
In all, 490 subjects were randomized to placebo, or imiquimod 2.5% or 3.75% cream. Median baseline lesion counts for the treatment groups were 9 to 10. Complete and partial clearance rates were 5.5% and 12.8% for placebo, 25.0% and 42.7% for imiquimod 2.5%, and 34.0% and 53.7% for imiquimod 3.75% (P < .001, each imiquimod vs placebo; P = .034, 3.75% vs 2.5% for partial clearance). Median reductions from baseline in lesion count were 23.6%, 66.7%, and 80.0% for the placebo, imiquimod 2.5%, and imiquimod 3.75% groups, respectively (P < .001 each imiquimod vs placebo). There were few treatment-related discontinuations. Temporary treatment interruption (rest) rates were 0%, 17.1%, and 27.2% for the placebo, imiquimod 2.5%, and imiquimod 3.75%, respectively.
LIMITATIONS:
Local effects of imiquimod, including erythema, may have led to investigator and subject bias.
CONCLUSIONS:
Both imiquimod 2.5% and 3.75% creams were more effective than placebo and had an acceptable safety profile when administered daily as a 3-week on/off/on regimen.
AuthorsC William Hanke, Kenneth R Beer, Eggert Stockfleth, Jason Wu, Theodore Rosen, Sharon Levy
JournalJournal of the American Academy of Dermatology (J Am Acad Dermatol) Vol. 62 Issue 4 Pg. 573-81 (Apr 2010) ISSN: 1097-6787 [Electronic] United States
PMID20133012 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
CopyrightCopyright 2009 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.
Chemical References
  • Adjuvants, Immunologic
  • Aminoquinolines
  • Dosage Forms
  • Imiquimod
Topics
  • Adjuvants, Immunologic (administration & dosage)
  • Administration, Topical
  • Adult
  • Aged
  • Aged, 80 and over
  • Aminoquinolines (administration & dosage)
  • Dosage Forms
  • Double-Blind Method
  • Drug Administration Schedule
  • Face
  • Female
  • Humans
  • Imiquimod
  • Keratosis, Actinic (drug therapy)
  • Male
  • Middle Aged
  • Scalp
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: